DAVID E. TRENTHAM, M.D.; MICHAEL E. WEINBLATT, M.D.; K. FRANK AUSTEN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Recalcitrance of the disease or the emergence of unacceptable drug side effects eventually make some patients with rheumatoid arthritis unsuitable for all medications, including gold or penicillamine, currently approved by the Food and Drug Administration for the management of that disease. In such patients, the physician currently has few options at the tertiary level of care to alleviate morbidity and slow further joint destruction. Ongoing research is directed to evaluating the use of lymphoplasmapheresis (1), leukapheresis (2), methotrexate (3), and fractionated total lymphoid irradiation (4, 5) for refractory patients. A recently completed, multicenter controlled trial (3) and a randomized crossover
TRENTHAM DE, WEINBLATT ME, AUSTEN KF. Total Lymphoid Irradiation in Tertiary Care for Rheumatoid Arthritis. Ann Intern Med. 1985;102:544–545. doi: 10.7326/0003-4819-102-4-544
Download citation file:
Published: Ann Intern Med. 1985;102(4):544-545.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use